AstraZeneca And Bristol Myers Squibb Reportedly Held Early Merger Talks For Potential $400 Billion Pharma Giant

AstraZeneca Plc and Bristol Myers Squibb reportedly held preliminary discussions about a possible merger that could create one of the world's largest pharmaceutical companies, with a combined market value of nearly $400 billion. According to a person familiar with the matter, the talks were at an early stage, although it remains unclear whether discussions are still ongoing. The potential deal was first reported by the Financial Times. AstraZeneca declined to comment on the report, while Bristol Myers Squibb did not immediately respond to requests for comment.

If pursued, the merger could face significant regulatory scrutiny, particularly in the United States. Analysts believe U.S. antitrust authorities under President Donald Trump's administration would closely examine the transaction because of overlapping drug portfolios and concerns about reduced competition. The deal could also attract attention since it would involve a UK-based pharmaceutical company acquiring one of America's largest drugmakers, despite the Trump administration's emphasis on strengthening domestic pharmaceutical manufacturing and investment. AstraZeneca itself has previously announced plans to pursue a direct U.S. stock market listing to benefit from stronger market valuations.

Both companies have strong positions in oncology, making competition concerns a key issue. AstraZeneca has experienced significant growth under CEO Pascal Soriot, with its share price rising more than fourfold during his 14-year leadership. The company's latest quarterly results showed continued strong demand for its cancer and rare disease medicines. In 2025, oncology products generated approximately $25 billion in revenue, accounting for nearly half of AstraZeneca's total sales, while cardiovascular, renal, and metabolism therapies contributed around $12 billion. Meanwhile, oncology medicines represented more than 40% of Bristol Myers Squibb's total sales during the first half of 2026, with several of its cancer immunotherapies directly competing against AstraZeneca's products.

Legal experts believe a merger of this scale would likely require extensive regulatory review and potentially significant divestitures. Antitrust lawyer Andre Barlow of DBM Law Group said the U.S. Federal Trade Commission would likely examine overlaps in marketed drugs as well as late-stage pipeline candidates. He noted that when Bristol Myers acquired Celgene for about $80 billion in 2019, regulators required the sale of psoriasis drug Otezla in a divestiture valued at $13.4 billion. According to Barlow, regulators are also expected to assess whether such a merger could reduce future innovation or give the combined company excessive market power through bundled products.

For Bristol Myers Squibb, a large acquisition could help offset the expected decline in revenue from several blockbuster medicines that are approaching patent expiration. The company's blood cancer drug Revlimid, acquired through the Celgene deal, has already lost patent protection, while top-selling products Opdivo and Eliquis are expected to face generic competition by 2028. At the same time, Bristol Myers has been strengthening its pipeline through smaller acquisitions and newer medicines, including the experimental blood thinner milvexian, anemia treatment Reblozyl, and heart disease therapy Camzyos. The company also recently raised its full-year revenue and profit guidance after reporting stronger-than-expected second-quarter results.

The reported discussions also highlight how rare large pharmaceutical mergers have become in recent years due to stricter antitrust oversight and ongoing pressure from U.S. policymakers to reduce drug prices. About a decade ago, AstraZeneca successfully resisted a takeover attempt by Pfizer, while other major industry transactions have included AbbVie's acquisition of Allergan in 2020, Takeda's purchase of Shire in 2019, and Bristol Myers' acquisition of Celgene. Whether AstraZeneca and Bristol Myers decide to move forward, any potential merger would likely become one of the most closely watched pharmaceutical deals in recent years.